Molecular Weight

Intact molecular weight analysis measures the total mass of a biopharmaceutical molecule without prior digestion, confirming that the product is intact and structurally as expected. It provides an assessment of product intactness, identifies any cleavages within the protein backbone, and gives an orthogonal view of post-translational modifications including glycoforms. It is a regulatory requirement under ICH Q6B for biopharmaceutical characterization.

The most widely used technique is online liquid chromatography with electrospray mass spectrometric detection using a Quadrupole-Time of Flight instrument (LC/ES-MS, Q-TOF). This allows high-resolution, high-sensitivity molecular weight determination of intact proteins and their glycoforms, as well as an assessment of protein backbone intactness. For heavily glycosylated or PEGylated proteins where high product heterogeneity compromises accurate LC/ES-MS analysis, MALDI-TOF-MS is used as an alternative, providing an average molecular weight across the heterogeneous population.

Intact molecular weight analysis provides information on product intactness, the presence of free light or heavy chains and half-antibody species for monoclonal antibody products, the major glycoforms present, and non-glycosylated species. When performed following reduction, de-N-glycosylation, or both, it progressively simplifies the molecular weight profile to allow a more detailed assessment of the underlying protein structure and any modifications present.

Biopharmaceuticals such as monoclonal antibodies carry significant glycan heterogeneity that complicates intact mass spectra. By analysing samples as received, following reduction of disulfide bonds, following de-N-glycosylation, and following both reduction and de-N-glycosylation, different layers of structural information are revealed at each stage. This progressive approach allows the contribution of glycosylation, chain structure and PTMs to be assessed independently and with greater confidence.

C-terminal heterogeneity in monoclonal antibodies arises because the C-terminal lysine residue on the heavy chain is variably present or absent, resulting in a mixture of molecular forms differing by 128 Da. This is a common and well-characterized post-translational modification. It is detected using a combination of intact molecular weight analysis of the released, de-N-glycosylated heavy chain, molecular weight analysis of C-terminal peptides, and peptide mapping. The relative proportions of each form can be quantified for batch-to-batch and biosimilar comparability assessments.

MALDI-TOF-MS is used when a protein carries significant glycosylation or PEGylation that creates too much heterogeneity for accurate intact mass measurement by LC/ES-MS Q-TOF. In these cases MALDI-TOF-MS provides an average molecular weight across the heterogeneous population, allowing an intact mass assessment where LC/ES-MS alone would be insufficient. Once heterogeneity is reduced — for example following desialylation and deglycosylation — LC/ES-MS can then be applied for more detailed analysis.

In biosimilar development, intact molecular weight data provide an early and sensitive comparability check between the biosimilar candidate and the reference product. Differences in glycoform profiles, chain integrity or PTM levels will be reflected in the intact mass spectrum, flagging potential structural divergence that warrants further investigation. Combined with peptide mapping and other orthogonal techniques, intact mass analysis contributes to the structural comparability package required by regulators including the FDA, EMA and MHRA.